|
Definition |
The combination of radiotherapy with LHRH ADT has definitively proven its superiority compared with
radiotherapy alone followed by deferred ADT on relapse, as shown by phase III randomised trials (Table 7.3.3). These trials included high risk prostate cancer patients, mostly by virtue of locally advanced (T3-T4 N0-X)disease, though with a wide range of clinical risk factors, such as PSA level or Gleason grade (high risk localised, T1-2, N0-X prostate cancer). The most powerful conclusion from these studies comes from the EORTC 22863 trial, which is the basis for the combination of radiotherapy and ADT in patients with locally advanced prostate cancer as standard practice today.
|